Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573287 · ClinicalTrials.gov registry record · NA
First Episode Schizophrenia and Cannabis-Related Disorder Study
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT00573287 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT00573287, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response. Preliminary evidence suggests that clozapine may uniquely reduce substance use in patients with schizophrenia. The purpose of this study is to establish an effective methodology for studying early treatment with clozapine in patients with co-occurring schizophrenia and cannabis use disorder, while generating pilot data comparing clozapine vs. risperidone on substance use, psychiatric symptoms, side effects, and treatment discontinuation.
Interventions
- DRUG clozapine
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573287
The ClinicalTrials.gov registry entry for NCT00573287 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clozapine is the first listed.
NCT00573287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00573287 about?
NCT00573287 is a clinical study titled "First Episode Schizophrenia and Cannabis-Related Disorder Study". Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response. Preliminary evidence suggests that clozapine may uniquely reduce substance use in patients with schizophrenia. The purpose of this study is to establ...
What is the current status of trial NCT00573287?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2006-06. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00573287?
The interventions under investigation include: clozapine (DRUG), risperidone (DRUG).
Who is sponsoring clinical trial NCT00573287?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.